US Federal and Business R&D Expenditure
Business R&D expenditure has surged to dominate U.S. innovation funding, reaching $600 billion in 2021 and accounting for 76% of national R&D spending, while federal R&D funding has declined from 67% in 1964 to 20% in 2019, reshaping the landscape of American technological advancement
Summary
Research and development (R&D) expenditure in the United States encompasses federal and business funding efforts, playing a pivotal role in driving innovation and technological advancement. Historically, federal funding has fluctuated significantly, influenced by economic conditions and policy changes, while business R&D has emerged as the dominant force, accounting for a substantial majority of total national R&D investment. The federal government’s involvement, particularly through agencies such as the Department of Defense (DOD) and the National Institutes of Health (NIH), remains critical, though its share of total R&D spending has decreased from 67% in 1964 to around 20% by 2019, raising questions about the sustainability of federal support for long-term scientific research[1][2].
In fiscal year 2022, federal obligations for basic research predominantly flowed to extramural performers, such as businesses and academic institutions, highlighting a trend where federal funding complements rather than replaces private investment. As of 2021, business R&D expenditure reached approximately $600 billion, representing 76% of national R&D spending, underscoring the private sector’s increasingly significant role in the nation’s innovation ecosystem[3][4]. Notably, industries such as pharmaceuticals and semiconductors have led this charge, capitalizing on tax incentives like the permanent R&D tax credit established in 2015, which incentivizes companies to enhance their research activities[5][6]. The relationship between federal and business R&D expenditure has raised important discussions around “crowding-in” effects, where federal funding reduces the risks associated with long-term investments in research, encouraging further private sector engagement. However, concerns persist regarding the focus of business in- vestments, which may prioritize short-term commercial gains over long-term societal benefits, potentially neglecting critical areas of basic research that are essential for groundbreaking innovations[7].
In recent years, particularly during the COVID-19 pandemic, there has been a resurgence in federal R&D funding, with expenditures peaking at $185 billion in 2021, reflecting a renewed commitment to science and technology[8]. As the landscape continues to evolve, understanding the dynamics between federal and private sector R&D expenditures remains vital to fostering a robust innovation environment that can effectively address both current and future challenges.
Overview of Federal R&D Expenditure
The landscape of federal research and development (R&D) expenditure in the United States has evolved significantly over the years, influenced by various factors including policy changes and economic conditions. Federal funding for basic and applied research saw notable increases during the late 1990s and early 2000s, primarily due to the NIH doubling initiative, which aimed to double the budget of the National Institutes of Health (NIH) over a five-year period from 1998 to 2003[1]. This period marked a shift in how the federal government approached R&D, emphasizing the importance of scientific research as a catalyst for innovation.
In fiscal year 2022, a significant majority (68%, or $30.8 billion) of federal obligations for basic research were directed towards extramural performers such as businesses, academic institutions, and nonprofit organizations[1]. The Department of Energy (DOE) emerged as a leading funder among intramural performers, allocating $4.7 billion, predominantly to federally funded research and development centers (FFRDCs)[1]. The Department of Health and Human Services (HHS) followed closely, committing $4.6 billion for similar purposes.
Despite the federal government’s declining direct spending on R&D as a share of the economy, which fell to just over 0.6% of GDP by 2018, it has continued to promote private sector R&D through mechanisms such as the R&D tax credit[5]. This credit, which became permanent in 2015, incentivizes businesses to increase their R&D activities, reflecting an increasing share of R&D tax incentives in total government support—from approximately 29% in 2000 to 38% in 2016[6]. Federal funding’s proportion of total U.S. R&D has fluctuated over the years, with a drop from 12% in 2010 to 9% in 2019, yet remaining a critical source of funding[6]. In recent years, especially during and after the COVID-19 pandemic, there has been a resurgence in federal R&D obligations, surpassing previous peaks with reported expenditures of $185 billion in 2021, largely due to supplemental funding from Congress[8]. The federal government continues to play a vital role in financing R&D across various sectors, with 33 federal institutions actively engaged in this mission[8]. Key agencies contributing to federal R&D funding include the Department of Defense (DOD), HHS, DOE, NASA, and the National Science Foundation (NSF), collectively representing 98% of total federal R&D spending in 2020[9].
Overview of Business R&D Expenditure
In 2021, business research and development (R&D) expenditure in the United States reached approximately $600 billion, with a significant increase of $69.2 billion from the previous year.[3][4] This growth underscores the business sector’s pivotal role in national R&D performance, which has been consistent over the years. By 2021, domestically performed business R&D accounted for 76% of the total national R&D expenditure, emphasizing the sector’s dominance in innovation and development efforts.[4]
Capital Expenditures for R&D
In 2021, companies that engaged in or funded R&D in the U.S. reported total capital expenditures of $793 billion, with $53 billion (7%) specifically allocated for assets used in domestic R&D operations.[3] The pharmaceutical and semiconductor industries were notable for their significant capital investments, spending $7.5 billion (14% of national capital expenditures) and $5 billion (9%), respectively, on R&D-related assets.[3]
Growth Trends
From 2010 to 2015, year-over-year increases in total R&D expenditures averaged $17.6 billion, reflecting a compound average growth rate (CAGR) of 4.0%.[4] This trend accelerated in the years leading up to 2020, with notable increases of $50.6 billion in 2017-18 and $61.8 billion in 2018-19, averaging a 7.7% growth rate during this period. The growth in business R&D has outpaced overall national R&D and GDP growth rates, highlighting the increasing importance of business investment in R&D initiatives.[10]
R&D-to-GDP Ratio
The ratio of total national R&D expenditures to gross domestic product (GDP), a key indicator of the nation’s commitment to research and innovation, was estimated at 3.40% in both 2020 and 2021. This figure exceeds the OECD average of 2.67% and indicates a robust prioritization of R&D within the U.S. economy.[4][10] The predominance of business investment in R&D has significantly contributed to the rise in this ratio, particularly as federal funding has declined relative to nonfederal spending.[2]
Comparison of Federal and Business R&D Expenditure
Overview of R&D Funding Sources
The landscape of research and development (R&D) funding in the United States is characterized by a significant disparity between federal and business expenditures. Historically, the private sector has been the dominant source of R&D funding, accounting for about 67% of national R&D spending in 2015, with businesses investing $333 billion that year.[11] In contrast, federal contributions represented approximately 24% of total R&D funding, while other sources, including universities and nonprofit organizations, provided the remaining 8%.[11]
Trends in Federal R&D Expenditure
Federal R&D funding has shown fluctuations over the years, particularly influenced by broader economic conditions and policy changes. For instance, federal R&D expenditures saw a resurgence in funding from fiscal years 2017 to 2021, reaching $185 billion in 2021, spurred by responses to the COVID-19 pandemic and increased legislative support for science and technology investments.[6] This marked an increase from previous years, with significant annual hikes noted after years of decline. Despite these increases, the federal government’s share of total R&D spending remains relatively low, having decreased as a percentage of GDP, with federal R&D spending recorded at just over 0.6% in 2018.[5] Moreover, the federal government primarily supports basic and applied research, with 51% of academic R&D funded by federal sources in 2017.[12]
Role of the Business Sector
Conversely, the business sector has increasingly taken on a larger role in basic research, rising from performing 21% of such research in 2010 to 32% by 2019.[10] This trend is particularly evident in industries like pharmaceuticals and information technology, which have ramped up their research efforts substantially. Furthermore, businesses funded 33% of U.S. basic research in 2019, highlighting a shift towards greater investment in R&D by the private sector.[10]
Interaction Between Federal and Private Sector R&D
Interestingly, federal funding often complements private sector investment rather than crowds it out. This “crowding-in” effect occurs when federal investments facilitate additional private sector R&D by reducing the financial risks associated with long-term research projects.[7] The reliance on federal funding has historically supported key advancements, such as those seen in the shale gas boom, illustrating the crucial role federal investments play in de-risking private sector initiatives.[7]
Challenges and Opportunities in R&D Expenditure
Federal Funding Dynamics
The landscape of federal funding for research and development (R&D) in the United States has experienced significant fluctuations over the decades. In 1964, the federal government funded 67% of all U.S. R&D expenditures, but this share has decreased markedly since then, falling to 20% by 2019[2][10]. This decline can be attributed to several factors, including the reduction of space-related R&D funding post-moon landing and an increase in business sector investments spurred by energy crises- [13][10]. As of 2019, federal funding accounted for 41% of basic research, 32% of applied research, and only 12% of experimental development[13].
Business Sector Growth
In contrast, the business sector has increasingly dominated R&D funding, providing the largest share for applied research (56%) and a substantial majority for experimental development (87%)[13][10]. This shift has led to a growing R&D-to-GDP ratio, driven by the expansion of R&D-dependent goods and services in both national and global markets[10]. The reliance on private sector funding introduces opportunities for innovation but also raises concerns about the sustainability and focus of research efforts that might prioritize short-term commercial gains over long-term public bene- fits[7].
Role of the Federal Government
Despite the decline in federal funding, the government remains critical for advancing national R&D agendas. It plays a pivotal role in addressing market failures by investing in basic and applied research that the private sector might overlook due to its high-risk nature[7]. For instance, federal initiatives have historically contributed to breakthroughs such as the U.S. shale gas boom, demonstrating the importance of government funding in fostering innovations that benefit society at large[7].
Tax Credits and Incentives
Another area of opportunity lies in R&D tax credits, which incentivize companies to invest in qualified research activities. However, many businesses are unaware of these credits and do not fully capitalize on them, which can limit the overall impact of private sector contributions to R&D[13]. Enhanced awareness and understanding of tax incentives could significantly increase business participation in research activities.